Year: 2018
Type: article
Abstract: Over the last 15 years, multiple generations of EGFR tyrosine kinase inhibitors (TKIs) have completely transformed the landscape of management of EGFR -mutated lung cancers but are rarely used in other settings. In the pre-molecular testing era, the 1 st generation reversible EGFR inhibitor, erlotinib, was shown to prolong survival in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of first- or second-line chemotherapy compared to placebo [overall survival (OS) was 6.7 vs . 4.7 months, hazard ratio (HR) 0.70, P<0.001] (1).
Source: Annals of Translational Medicine
Authors: Mariam Alexander, Balazs Halmos
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2901604935